Calluna Pharma

📢We are hiring! We are looking to strengthen our team with two individuals passionate about clinical development and experienced in supporting clinical trial operations.   As 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 / 𝗩𝗣 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 you will be responsible for leading the internal clinical study team, managing external collaborators/partners, and oversee the study CROs and clinical service suppliers to achieve successful execution of clinical study(ies) with our lead candidate CAL101. Learn more about the role here ➡ https://lnkd.in/e5tDMJJ9   As a 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗖𝗼𝗼𝗿𝗱𝗶𝗻𝗮𝘁𝗼𝗿 / 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 you will be part of our clinical operation team and take part in day-to-day work to support a wide range of activities within clinical development. Learn more about the role here ➡ https://lnkd.in/ex5cKQWi This is a great time to join our team – learn more about our work on our website and send your application to renate.birkeli@callunapharma.com #Hiring #NewRole #ClinicalTrials

📅 May is Arthritis Awareness Month – a time to bring attention to this debilitating autoimmune condition affecting over 350 million people worldwide. In cases of rheumatoid arthritis, the immune system attacks the cells that line the joints, causing pain, swelling and stiffness. Over time, chronic inflammation can damage the joint itself, the cartilage and nearby bone. There is no cure for RA, but early diagnosis and appropriate treatment enables many people with this condition to have periods of months or even years between flare-ups and to be able to lead full lives. Current treatment options include taking long-term medications that can help relieve symptoms and receiving supportive treatments such as physiotherapy to assist with keeping mobile and finding ways around any problems surrounding daily activities. As treatments for rheumatoid arthritis and other autoimmune conditions continue to evolve, precision targeting approaches hold significant promise. At Calluna Pharma we have developed a robust pipeline of first-in-class therapeutic antibodies that aim to tackle the root causes of inflammation and fibrosis. 🎯 Our clinical stage lead program, CAL101, is a therapeutic monoclonal antibody that neutralizes the bioactivity of S100A4, a DAMP protein implicated in chronic activation of inflammatory signaling pathways and sustained fibrogenesis. By targeting upstream amplifiers of disease, we aim to fulfill unmet clinical needs across a spectrum of diseases such as idiopathic pulmonary fibrosis, chronic kidney disease, systemic sclerosis, rheumatoid arthritis, and severe (steroid insensitive) asthma. If you'd like to learn more about our work and therapeutic pipeline, visit our website: https://lnkd.in/e37y2VKy #ArthritisAwarenessMonth #PrecisionMedicine #Immunology #RheumatoidArthritis #Inflammation

Calluna’s CMO and co-founder Jonas Hallén, and board member Antoine Boulanger will be attending the 5th Norwegian Life Science Investor Partnering Day on May 15th. This year's event is all about exploring the intersection of biology, biotechnology, and digital solutions. Nordic and Norwegian life science investors focusing on health, bioindustrials, sustainability and life science based solutions, will meet and partner 1:1 with life science companies and other investors. If you want to hear more about our work, join Antoine and Jonas during their Fireside chat taking place at 14:05. Learn more and find the full agenda here: https://lnkd.in/eCnui8Kx #LifeSciences #InvestorDay

Calluna Pharma is attending Bio€quity Europe conference, taking place 12-14 May, organized by BioCentury Inc. and EBD Group. Our CEO John Montana is going to be in San Sebastian next week for one of Europe’s top experiences for CEOS and investors to network, partner and discuss key issues facing the biotech industry. This is an opportunity to learn more about how to reach discussion stage with investors, discover 100+ emerging biotechs, and dive into European biotech trends. Find out more, and join us here: https://lnkd.in/dzunkQc #Biotech #Pharma #VentureCapital #BioEquityEurope #BioEquity

We are delighted to welcome Margrethe Sørgaard to Calluna Pharma as Senior Vice President of Clinical Operations and Pharmacovigilance.   Bringing extensive experience from different leading positions in clinical development and operation, medical affairs, and drug safety / pharmacovigilance, Margrethe will play a pivotal role in supporting the strategic development of our clinical programs as we continue to grow.   Great to have you in the team Margrethe!   Read the full press release on our website: https://lnkd.in/eVtK8PTF   #PressRelease #NewHire #ClinicalOperations  

BioCentury Inc. recently spoke to our CEO, John Montana, for an ‘Emerging company profile’ article on Calluna Pharma – featuring exclusive insights about the story behind the merger, Calluna’s mission, and therapeutic pipeline. Sharing an update about Calluna’s lead clinical program, CAL101, John mentioned that safety and pharmacokinetic data are expected this summer, after which the program will enter a Phase II trial looking at fibrotic and inflammatory / autoimmune indications. Find a link to the full article in the comments, below. #Biotech #Biopharma #Immunology #Clinical #Innovation

Today, on World Kidney Day, we aim to raise awareness about Chronic Kidney Disease (CKD), impacting over 850 million people globally and leading to more than 3.1 million deaths in 2019. Over the last three decades, CDK treatment efforts have centered on preparing for and delivering kidney replacement therapies. However, recent therapeutic breakthroughs offer the opportunity to prevent or delay disease progression and mitigate complications such as cardiovascular disease and kidney failure, ultimately improving patient outcomes. At Calluna Pharma we are developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. 🚀 At the forefront of our portfolio is CAL101, a monoclonal antibody that neutralizes the bioactivity of S100A4, a DAMP protein implicated in serious and life-threatening diseases such as chronic kidney disease, severe (steroid insensitive) asthma, and pulmonary fibrosis. In chronically diseased tissues, S100A4’s inappropriate upregulation switches self-limiting tissue repair responses into chronic activation of inflammatory signaling pathways and sustained fibrogenesis. With CAL101, we aim to shift the paradigm, offering hope to patients grappling with serious and potentially life-threatening diseases such as chronic kidney disease. If you'd like to learn more about our work and therapeutic pipeline, visit our website: https://lnkd.in/e37y2VKy #WorldKidneyDay2024 #Immunology #PrecisionMedicine #ChronicKidneyDisease #CKD

Calluna Pharma is attending #BioEuropeSpring, March 18-20! Our CEO, John Montana, and Chief Medical Officer & Co-Founder, Jonas Hallén, are going to be in Barcelona next week for one of Europe's premier springtime partnering events, featuring multiple networking opportunities and a carefully curated program providing insights into the latest trends, challenges, and opportunities in the sector. Find out more, and join us here: https://lnkd.in/ee6-YHVa

Our CEO John Montana spoke with BioWorld News following the announcement of our official company launch and €75 million (US$81 million) Series A financing to advance neutralizing antibodies targeting proinflammatory molecules that drive inflammatory and fibrotic diseases. In the interview John outlines how the funding will be used over the next three years to drive phase IIa data generation across three indications.   ➡️CAL-101, targeting S100A4, is currently in a Phase Ib trial, with results anticipated in the first half of this year. Future plans include Phase IIa proof-of-concept (PoC) studies addressing fibrotic and chronic inflammatory diseases. ➡️CAL-102, targeting oxidised phospholipids (OxPL), is progressing through preclinical development for myocardial infarction induced reperfusion injury, with Phase I development slated for 2025. The funding will propel its progression to generate Phase IIa clinical PoC data in a comparable timeframe to the CAL101 clinical readouts. ➡️CAL-103 will also progress to a Phase Ib biomarker data readout in an inflammatory indication by mid 2026. Read the full interview here: https://rb.gy/pyapsv #Biotech #Biopharma #Immunology #Clinical #Innovation

‘What will shape the biotech industry in 2024?’🔍 Our CEO, John Montana, recently spoke to Labiotech.eu about his 2024 predictions for biotech. One thing John mentioned is that after a challenging year, companies with emerging clinical pipelines poised to reach clinical PoC within their current funding round, are well placed for further investment – as such companies would not only be seen as attractive candidates for potential M&A, but also, assuming favorable market conditions, IPO. Speaking about the importance of diversified and relevant company assets, John added that “Success also hinges on a diversified portfolio, which mitigates investor single asset risk. Additionally, strategic alignment with diseases of high pharma interest, opens doors for licensing opportunities providing access to non-dilutive funding and potential acquisition. With a focus on immunology, and a pipeline of first-in-class clinical antibodies, Calluna Pharma, addresses these key benchmarks for 2024 and beyond” Read more here: https://bit.ly/42beMZz #Biotech #Innovation #Biopharma #Immunology #Clinical